YMABY-Mabs Therapeutics Inc

The dominant driver of YMAB's share price in 2025 was the announced acquisition by SERB Pharmaceuticals at $8.60 per share in cash.

Before the announcement, the company had been pressured by biotech-sector weakness, negative earnings, limited revenue scale, and investor caution around small commercial oncology companies.

The acquisition created a sharp one-time repricing because the offer represented a roughly 105% premium to the prior closing price and largely capped upside near the tender price.

Fundamental factors such as quarterly revenue of about $19.5 million, net loss of about $3.2 million, and diluted EPS of negative $0.07 mattered less after the deal announcement because merger completion became the central valuation event.

After SERB completed the tender offer and merger in September 2025, Y-mAbs was delisted, so public market price drivers effectively ceased to apply to YMAB shares.

In August 2025, SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics in an all-cash transaction valued at about $412 million.

The offer price was $8.60 per share, representing a major premium to the stock's prior trading level and causing YMAB shares to surge after the announcement.

SERB launched the tender offer on August 18, 2025, and it expired on September 15, 2025.

On September 16, 2025, SERB announced that it had completed the acquisition, accepted validly tendered shares, completed the statutory merger, and made Y-mAbs a wholly owned subsidiary.

Following the transaction, Y-mAbs was delisted from the Nasdaq Global Select Market, and untendered shares were converted into the right to receive $8.60 in cash.

The broader biotechnology market remains highly selective, especially for small-cap companies with limited revenue, negative earnings, and concentrated clinical risk.

Investors have favored companies with strong balance sheets, clear catalysts, approved products, or acquisition potential while penalizing firms with uncertain funding needs.

Rare oncology remains attractive because high unmet need, specialized treatment centers, and regulatory incentives can support meaningful value for differentiated therapies.

Antibody-based therapeutics, including monoclonal antibodies, antibody-drug conjugates, and radioimmunotherapy approaches, continue to be major areas of innovation in cancer treatment.

The YMAB acquisition reflects a broader trend in which larger specialty pharmaceutical companies acquire smaller biotech firms to gain approved rare disease assets and strengthen targeted oncology portfolios.